Stories

Fruit-flavoured vapes are playing a major role in UK stop smoking services, with quit rates reportedly outperforming other forms of support. For many adult smokers, flavours are not a gimmick — they can make lower-risk alternatives more acceptable and help distance users from the taste of cigarettes. Restricting flavours may weaken one of the tools currently helping people quit combustible tobacco. Evidence-based policy should protect young people without removing options that support adult smoking cessation.

Tobacco harm reduction belongs within the wider harm reduction movement. The goal is not to celebrate nicotine use, but to reduce the disease and death caused by combustible cigarettes. When adult smokers switch to lower-risk alternatives, public health gains are possible even without complete nicotine abstinence. A consistent harm reduction approach should prioritise safer choices, accurate information and respect for real-world behaviour.

The harms of smoking do not stop with the smoker — and neither do the benefits of quitting. When adults move away from combustible cigarettes, families and communities can see reduced exposure to smoke, odour and tobacco-related risks. Harm reduction extends that logic by supporting realistic routes away from smoking, including lower-risk smoke-free alternatives. Public health should recognise not only secondhand smoke, but the wider benefits of secondhand quitting.

Tobacco harm reduction should be integrated into drug and alcohol services, where smoking rates often remain high and quitting support is limited. People who use drugs are frequently left behind by mainstream tobacco control, despite facing some of the greatest smoking-related health burdens. Offering accurate information and access to lower-risk nicotine alternatives could create more realistic pathways away from cigarettes. Harm reduction should apply to smoking too.

Before accepting dominant narratives on nicotine, the evidence deserves closer examination. Claims about vaping, youth uptake or harm reduction often become policy arguments before the data are properly tested. When evidence shows declining smoking, falling youth vaping or major differences in relative risk, public health should adjust its assumptions. Better nicotine policy starts with asking whether the narrative fits the facts.

US tobacco policy remains heavily focused on youth nicotine uptake, even as smoking continues to cause the greatest harm. Recent data suggest that youth vaping has fallen substantially, while adult smokers still need realistic routes away from combustible cigarettes. Protecting young people is essential, but it should not come at the cost of blocking harm reduction for adults. Public health policy should follow the scale of harm, not only the loudest political concern.

Global tobacco policy is still struggling to separate nicotine use from the harms of smoking. A harm reduction approach recognises that adults who cannot or do not want to quit nicotine should still have access to safer alternatives than combustible cigarettes. The challenge is not only scientific, but institutional: evidence on relative risk often clashes with entrenched ideology. Public health should focus on reducing disease and death, not defending outdated assumptions about nicotine.

Innovative nicotine products can affect more than individual smokers — they can also benefit families and households. When adults switch away from combustible cigarettes, exposure to smoke, odour and smoking-related harm may be reduced for those around them. Harm reduction is not about ignoring risk, but about choosing safer pathways where nicotine use already exists. Public health policy should recognise the wider benefits of smoke-free alternatives for consumers, families and communities.

Prohibition does not remove nicotine use — it reshapes where and how it happens. When safer products are banned or heavily restricted, consumers may be pushed towards illicit markets, unsafe supply chains and continued cigarette smoking. The social costs can include criminalisation, stigma, enforcement burdens and widening inequalities. Harm reduction offers a more practical path: reduce risk, preserve access to safer alternatives and regulate behaviour that already exists.

Switzerland’s move towards national cannabis legalisation reflects a more pragmatic approach to drug policy. Rather than relying on prohibition, the proposed model focuses on regulated access, consumer protection, quality control and prevention. The aim is not to present cannabis as risk-free, but to manage real-world use through oversight instead of leaving consumers to illicit markets. Evidence-based regulation should reduce harm, protect young people and bring existing demand into accountable systems.